namuscla
lupin europe gmbh - mexiletine hydrochloride - myotonic motnje - srčna terapija - namuscla je primerna za simptomatsko zdravljenje myotonia pri odraslih bolnikih z ne-dystrophic myotonic motnje.
parnido 3 mg tablete s podaljšanim sproščanjem
krka, d.d., novo mesto - paliperidon - tableta s podaljšanim sproščanjem - paliperidon 3 mg / 1 tableta - paliperidon
parnido 6 mg tablete s podaljšanim sproščanjem
krka, d.d., novo mesto - paliperidon - tableta s podaljšanim sproščanjem - paliperidon 6 mg / 1 tableta - paliperidon
parnido 9 mg tablete s podaljšanim sproščanjem
krka, d.d., novo mesto - paliperidon - tableta s podaljšanim sproščanjem - paliperidon 9 mg / 1 tableta - paliperidon
leqvio
novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - sredstva za spreminjanje lipidov - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
epiduo 1 mg/25 mg v 1 g gel
adapalen; benzoilperoksid - gel - adapalen 1 mg / 1 g benzoilperoksid25 mg / 1 g; benzoilperoksid 25 mg / 1 g - adapalen, kombinacije
parnido 3 mg tablete s podaljšanim sproščanjem
paliperidon - tableta s podaljšanim sproščanjem - paliperidon 3 mg / 1 tableta - paliperidon
parnido 6 mg tablete s podaljšanim sproščanjem
paliperidon - tableta s podaljšanim sproščanjem - paliperidon 6 mg / 1 tableta - paliperidon
zykalor 15 mg tablete
aripiprazol - tableta - aripiprazol 15 mg / 1 tableta - aripiprazol
kapruvia
vifor fresenius medical care renal pharma france - difelikefalin - pruritus - vsi drugi terapevtski izdelki - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.